A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Cisplatin - Etoposide (CE) Treatment of Patients With Metastatic Lung Carcinoma (ACE).

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 09 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aprepitant (Primary) ; Cisplatin; Dexamethasone; Etoposide; Ondansetron
Indications Chemotherapy-induced nausea and vomiting
Focus Pharmacokinetics
Acronyms ACE

03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
11 Dec 2009 Trial sponsor changed from (Merck Sharp & Dohme) to Merck and Co as reported by ClinicalTrials.gov.
24 Jul 2009 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com